Avricore Health Inc. (AVCRF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.48 Million CAD | 97.08% |
| 2022 | 1.76 Million CAD | 1339.95% |
| 2021 | 122.8 Thousand CAD | 271.81% |
| 2020 | 33.03 Thousand CAD | 0.09% |
| 2019 | 33 Thousand CAD | -85.43% |
| 2018 | 226.44 Thousand CAD | -57.89% |
| 2017 | 537.71 Thousand CAD | -46.95% |
| 2016 | 1.01 Million CAD | 17643.57% |
| 2015 | 5713.00 CAD | -93.15% |
| 2014 | 83.36 Thousand CAD | 0.0% |
| 2013 | 83.36 Thousand CAD | 0.0% |
| 2012 | 83.36 Thousand CAD | -72.72% |
| 2011 | 305.59 Thousand CAD | -79.06% |
| 2010 | 1.45 Million CAD | 417.14% |
| 2009 | 282.26 Thousand CAD | 13.34% |
| 2008 | 249.04 Thousand CAD | -2.81% |
| 2007 | 256.24 Thousand CAD | 14.61% |
| 2006 | 223.58 Thousand CAD | -6.56% |
| 2005 | 239.27 Thousand CAD | 114.86% |
| 2004 | 111.36 Thousand CAD | 2157.51% |
| 2003 | 4933.00 CAD | 37.83% |
| 2002 | 3579.00 CAD | 0.0% |
| 2001 | - CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.04 Million CAD | -7.04% |
| 2024 Q1 | 1.12 Million CAD | -16.99% |
| 2023 Q2 | 548.04 Thousand CAD | -12.9% |
| 2023 Q4 | 1.35 Million CAD | 42.05% |
| 2023 Q3 | 953.45 Thousand CAD | 73.97% |
| 2023 FY | 3.48 Million CAD | 97.08% |
| 2023 Q1 | 629.24 Thousand CAD | -35.61% |
| 2022 FY | 1.76 Million CAD | 1339.95% |
| 2022 Q1 | 42.73 Thousand CAD | 21.44% |
| 2022 Q2 | 176.17 Thousand CAD | 312.24% |
| 2022 Q3 | 572.22 Thousand CAD | 224.81% |
| 2022 Q4 | 977.23 Thousand CAD | 70.78% |
| 2021 Q2 | 4939.00 CAD | -34.8% |
| 2021 FY | 122.8 Thousand CAD | 271.81% |
| 2021 Q3 | 75.1 Thousand CAD | 1420.63% |
| 2021 Q4 | 35.19 Thousand CAD | -53.14% |
| 2021 Q1 | 7575.00 CAD | -6.27% |
| 2020 FY | 33.03 Thousand CAD | 0.09% |
| 2020 Q4 | 8082.00 CAD | 0.0% |
| 2020 Q3 | 8082.00 CAD | -4.72% |
| 2020 Q2 | 8482.00 CAD | 1.17% |
| 2020 Q1 | 8384.00 CAD | 115.45% |
| 2019 FY | 33 Thousand CAD | -85.43% |
| 2019 Q3 | 16.22 Thousand CAD | -21.72% |
| 2019 Q2 | 20.73 Thousand CAD | -58.78% |
| 2019 Q1 | 50.3 Thousand CAD | 158.85% |
| 2019 Q4 | -54.26 Thousand CAD | -434.37% |
| 2018 FY | 226.44 Thousand CAD | -57.89% |
| 2018 Q4 | -85.47 Thousand CAD | -2790.73% |
| 2018 Q3 | -2957.00 CAD | -101.85% |
| 2018 Q2 | 159.78 Thousand CAD | 3.03% |
| 2018 Q1 | 155.09 Thousand CAD | 37.81% |
| 2017 Q3 | 124.44 Thousand CAD | -30.96% |
| 2017 FY | 537.71 Thousand CAD | -46.95% |
| 2017 Q1 | 120.48 Thousand CAD | 966.72% |
| 2017 Q2 | 180.24 Thousand CAD | 49.6% |
| 2017 Q4 | 112.53 Thousand CAD | -9.57% |
| 2016 Q1 | 470.89 Thousand CAD | 888.6% |
| 2016 FY | 1.01 Million CAD | 17643.57% |
| 2016 Q2 | 132.18 Thousand CAD | -71.93% |
| 2016 Q4 | 11.29 Thousand CAD | -97.17% |
| 2016 Q3 | 399.31 Thousand CAD | 202.08% |
| 2015 FY | 5713.00 CAD | -93.15% |
| 2015 Q4 | 47.63 Thousand CAD | -57.34% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q2 | 5713.00 CAD | 0.0% |
| 2015 Q3 | 111.65 Thousand CAD | 1854.45% |
| 2014 Q3 | - CAD | -100.0% |
| 2014 Q2 | 83.36 Thousand CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 FY | 83.36 Thousand CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | -100.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | 83.36 Thousand CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | 83.36 Thousand CAD | 0.0% |
| 2012 FY | 83.36 Thousand CAD | -72.72% |
| 2012 Q2 | 3018.00 CAD | 530.06% |
| 2012 Q3 | - CAD | -100.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q1 | 479.00 CAD | -98.75% |
| 2011 Q1 | 52.27 Thousand CAD | -95.12% |
| 2011 FY | 305.59 Thousand CAD | -79.06% |
| 2011 Q3 | 41.65 Thousand CAD | -65.68% |
| 2011 Q4 | 38.2 Thousand CAD | -8.27% |
| 2011 Q2 | 121.35 Thousand CAD | 132.16% |
| 2010 Q2 | -5155.00 CAD | -101.31% |
| 2010 Q3 | 82.63 Thousand CAD | 1703.08% |
| 2010 Q1 | 394.75 Thousand CAD | -60.39% |
| 2010 Q4 | 1.07 Million CAD | 1194.89% |
| 2010 FY | 1.45 Million CAD | 417.14% |
| 2009 Q1 | 87.75 Thousand CAD | 60.1% |
| 2009 Q2 | 84.03 Thousand CAD | -4.23% |
| 2009 Q3 | 73.42 Thousand CAD | -12.62% |
| 2009 Q4 | 996.65 Thousand CAD | 1257.31% |
| 2009 FY | 282.26 Thousand CAD | 13.34% |
| 2008 FY | 249.04 Thousand CAD | -2.81% |
| 2008 Q4 | 54.81 Thousand CAD | -1.53% |
| 2008 Q3 | 55.66 Thousand CAD | -24.13% |
| 2008 Q2 | 73.36 Thousand CAD | 9.74% |
| 2008 Q1 | 66.84 Thousand CAD | 25.42% |
| 2007 Q3 | 55.53 Thousand CAD | -9.6% |
| 2007 Q2 | 61.43 Thousand CAD | -15.71% |
| 2007 Q1 | 72.87 Thousand CAD | 13.24% |
| 2007 Q4 | 53.29 Thousand CAD | -4.03% |
| 2007 FY | 256.24 Thousand CAD | 14.61% |
| 2006 Q4 | 64.35 Thousand CAD | 11.78% |
| 2006 Q1 | 47.69 Thousand CAD | -20.89% |
| 2006 Q2 | 58.72 Thousand CAD | 23.13% |
| 2006 Q3 | 57.57 Thousand CAD | -1.96% |
| 2006 FY | 223.58 Thousand CAD | -6.56% |
| 2005 Q1 | 46.4 Thousand CAD | -14.64% |
| 2005 Q2 | 77.5 Thousand CAD | 67.02% |
| 2005 Q3 | 56.88 Thousand CAD | -26.61% |
| 2005 Q4 | 60.28 Thousand CAD | 5.98% |
| 2005 FY | 239.27 Thousand CAD | 114.86% |
| 2004 FY | 111.36 Thousand CAD | 2157.51% |
| 2004 Q4 | 54.36 Thousand CAD | -14.8% |
| 2004 Q3 | 63.81 Thousand CAD | 49.9% |
| 2004 Q2 | 42.57 Thousand CAD | -19.26% |
| 2004 Q1 | 52.72 Thousand CAD | 218.63% |
| 2003 Q1 | 225.00 CAD | 0.0% |
| 2003 Q4 | 16.54 Thousand CAD | 0.0% |
| 2003 Q3 | - CAD | -100.0% |
| 2003 FY | 4933.00 CAD | 37.83% |
| 2003 Q2 | 3767.00 CAD | 1574.22% |
| 2002 Q4 | - CAD | -100.0% |
| 2002 FY | 3579.00 CAD | 0.0% |
| 2002 Q3 | 632.00 CAD | 0.0% |
| 2001 FY | - CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | -281.725% |
| Arrayit Corporation | 4.37 Million USD | 20.381% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | 86.522% |
| Bioqual, Inc. | 58.59 Million USD | 94.052% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | 77.215% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 99.953% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | 45.256% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | -231.417% |
| Interpace Biosciences, Inc. | 40.21 Million USD | 91.333% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | -678.806% |
| InVitro International | 792.62 Thousand USD | -339.695% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | 68.69% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | 51.758% |
| NovelStem International Corp. | 12 Thousand USD | -28942.892% |
| Optigenex Inc. | 465.97 Thousand USD | -647.934% |
| PharmChem, Inc. | 6.01 Million USD | 42.034% |
| Proteome Sciences plc | 6.4 Million USD | 45.55% |
| Response Genetics, Inc | 18.04 Million USD | 80.681% |
| Rennova Health, Inc. | 13.03 Million USD | 73.266% |
| RushNet, Inc. | 1.78 Million USD | -94.932% |
| ScreenPro Security Inc. | 1.91 Million USD | -82.077% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | 8.167% |
| Todos Medical Ltd. | 7.69 Million USD | 54.709% |